At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3 enrolled
Drug / intervention
Linagliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
In Brief
A clinical study evaluating Linagliptin and Glipizide for Chronic Kidney Diseases and Type 2 Diabetes. Completed, enrolled 3 participants across 1 site.
Detailed Summary
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases, Type 2 Diabetes
CountriesUnited States
CollaboratorsAmerican Diabetes Association, Medtronic, Abbott
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedNov 2015
Primary CompletionAug 2017
Study CompletionAug 2018
TodayJul 2026
First PostedNov 18, 2015
Enrollment StartNov 1, 2015
Primary CompletionAug 1, 2017
Study CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.6 years ago
Interventions
Linagliptindrug
Receives 4 weeks of study drug linagliptin
Glipizidedrug
Receives 4 weeks of study drug glipizide